Introduction
Compounded sermorelin peptide therapy is an innovative, off-label approach for adults seeking weight loss, especially those who cannot tolerate GLP-1 agonists such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), or similar medications, or those of you who are not candidates for GLP-1 agonist therapy in the first place. Sermorelin is a man-made peptide that mimics the first 29 amino acids of the body’s natural growth hormone-releasing hormone (GHRH). Basically, there’s a hormone that tells your brain to release another hormone.
When administered subcutaneously (into the fat under the skin), sermorelin stimulates your pituitary gland (in the middle of your brain) to release endogenous growth hormone (GH) in a physiologically regulated, pulsatile manner. This natural stimulation of GH leads to increased production of insulin-like growth factor 1 (IGF-1) in your liver, which in turn drives many of the metabolic and anabolic effects associated with GH.
The scientific rationale for using sermorelin for weight loss is based on the well-established role of GH in promoting lipolysis (the breakdown of fat), reducing visceral adiposity (abdominal or belly fat), and preserving or increasing lean muscle mass. In those who are overweight or obese, GH secretion is often blunted, contributing to fat accumulation and overall metabolic dysfunction. By enhancing endogenous GH secretion, sermorelin may help counteract these effects, supporting healthier body composition and metabolic health. Unlike direct GH injections, sermorelin’s action is subject to your body’s natural feedback mechanisms, reducing the risk of excessive GH levels and associated side effects.
Although most clinical data on sermorelin come from its use in children with growth hormone deficiency, where it has been shown to be both safe and effective for promoting growth, the underlying mechanism is directly relevant to adults seeking weight loss. Preclinical studies and trials with related GHRH analogues in adults have demonstrated reductions in visceral fat, improvements in cardiovascular risk markers, and favorable changes in body composition, all without significant adverse effects on glucose metabolism or other safety concerns. This makes compounded sermorelin an attractive option for adults who are not candidates for, or cannot tolerate, GLP-1 agonists.
Why Sermorelin for Weight Loss?
Sermorelin offers a unique set of benefits for adults seeking weight loss, particularly those who have experienced intolerable side effects or limited access to GLP-1 agonists. Its mechanism of action, safety profile, and patient experience distinguish it from other commonly prescribed weight loss medications such as phentermine and orlistat.
Benefits over GLP-1 Agonists
GLP-1 agonists, including semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, and Zepbound, are highly effective for weight loss but are frequently associated with gastrointestinal side effects such as nausea, vomiting, diarrhea, and abdominal pain. These symptoms are dose-dependent and often lead to discontinuation or intolerance in a significant proportion of patients. In general, patients who slowly increase their dose and do not delay injections tend to do well, without significant side effects. At most, these patients complain of 1-3 days of mild nausea after each injection. Others complain of upper abdominal discomfort that they attribute to acid reflux, which may be related to the pharmacologic effect of delayed gastric emptying. In addition, GLP-1 agonists can cause less common but serious side effects such as pancreatitis, gallbladder disease, and hypersensitivity reactions. These patients often end up in the ER with me and sometimes get admitted to the hospital for removal of the gallbladder or for IV fluids. The high cost and frequent insurance denials for these medications further limit their accessibility for many adults.
In contrast, compounded sermorelin peptide therapy is not associated with gastrointestinal side effects, as it does not act on the gut or central appetite pathways. Instead, it works by stimulating the body’s own GH production, leading to increased fat breakdown and improved body composition without provoking nausea or digestive discomfort. Patient-reported experiences with compounded sermorelin consistently highlight its superior tolerability, with the most common side effects being mild and transient, such as injection site reactions and facial flushing. These positive experiences are especially valued by adults who have discontinued GLP-1 agonists due to intolerable side effects or who are unable to access these medications due to cost or insurance barriers.
Surveys of patients using compounded medications, including hormone therapies similar to sermorelin, reveal high satisfaction rates, with more than 95% of respondents expressing satisfaction with all aspects of their therapy except for cost. Patients report that compounded medications are equally good or better than previous therapies, and the ability to customize dosing and formulation enhances both satisfaction and adherence.
Benefits of Sermorelin Peptide over Phentermine and Orlistat
Phentermine and orlistat are two other widely prescribed oral weight loss medications in the United States. Phentermine is a sympathomimetic amine that suppresses appetite by increasing norepinephrine release in the brain. It is only approved for short-term use (up to 12 weeks) and produces a mean weight loss of approximately 4–6% of baseline body weight over six months, with more than 40% of patients achieving at least 5% weight loss. The combination of phentermine with topiramate yields even greater weight loss, with 8–10% reductions in body weight over one year. However, phentermine is associated with side effects such as dry mouth, insomnia, headache, and constipation, and is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, glaucoma, or a history of substance use disorder.
Orlistat is a pancreatic lipase inhibitor that reduces dietary fat absorption by about 30%, leading to modest weight loss of 2.8–4.8% of baseline body weight over one year. Its use is limited by frequent gastrointestinal side effects, including flatulence and steatorrhea (fatty or oily diarrhea), which often lead to discontinuation. Orlistat may also cause malabsorption of fat-soluble vitamins, leading to costly supplementation.
Sermorelin stands out from phentermine and orlistat in several key ways. First, its mechanism of action is physiologically regulated, promoting fat loss and lean mass preservation without interfering with natural processes in the body. Second, its safety profile is favorable, with only mild and transient side effects reported in clinical studies. Third, sermorelin does not carry the cardiovascular risks associated with phentermine or the bothersome gastrointestinal effects of orlistat. Finally, compounded sermorelin can be customized to individual patient needs, offering flexibility in dosing and formulation that is not possible with standard oral medications.
The Advantages of Compounded Sermorelin Peptide
Obtaining sermorelin as a compounded medication offers several important advantages over standard commercial options, particularly for adults seeking weight loss who are not candidates for GLP-1 agonists. Compounded sermorelin is prepared by specialized pharmacies that can customize the dosage, concentration, and formulation to meet individual patient needs.
One of the most significant benefits of compounded sermorelin is improved accessibility. Because sermorelin is not FDA-approved for weight loss and is not commercially available for this indication, local retail pharmacies generally do not stock it. Compounding pharmacies, regulated primarily by state boards of pharmacy, can prepare sermorelin in the exact dosage and formulation prescribed by the physician, ensuring that patients receive a product tailored to their specific needs. Mail-order and delivery services offered by compounding pharmacies further enhance accessibility, especially for patients in remote areas or those with mobility limitations.
Cost is another important consideration. While compounded medications are generally more expensive than generic versions of the same medication, they tend to be less expensive than brand name GLP-1 agonists, which can cost over $1,000 per month. Most people don’t realize that insurance companies rarely help cover the cost of these medications, even for morbidly obese individuals who stand to benefit greatly from GLP-1 agonists. This is despite frustrating attempts at prior authorizations and subsequent appeals, resulting only in delays. This leads to many patients searching for other options.
That being said, semaglutide or tirzepatide, in a compounded form, can be a cost-effective option for those who cannot tolerate brand name medications or those who may benefit from customized dosing plans.
I often prescribe compounded sermorelin to overweight patients who do not meet BMI criteria for GLP-1 agonists. Rather than waiting for them to gain more weight before meeting criteria, it is generally more prudent to try something like compounded sermorelin peptide to kickstart their weight loss and fitness journey.
Regulatory and quality assurance standards for compounding pharmacies are designed to ensure product safety and consistency. Pharmacies that prepare compounded sermorelin must adhere to United States Pharmacopeia (USP) Chapter 797 standards for sterile compounding, which include requirements for facility design, environmental controls, personnel training, and end-product testing. Patients and providers should select compounding pharmacies that are accredited by recognized organizations and can provide documentation of their quality assurance programs. Despite oversight by state boards of pharmacy, not all compounded medications are created equally. Remember to review the Certificate of Analysis before choosing to introduce a compounded substance into your body.
Dosing Sermorelin Peptide
Effective use of compounded sermorelin for weight loss requires careful attention to dosing, administration, and monitoring protocols. While there are no formal guidelines for sermorelin use in adults for weight loss, recommendations can be extrapolated from established protocols for growth hormone deficiency and related therapies.
Dosing and Administration
Compounded sermorelin is typically administered as a subcutaneous injection once daily at bedtime, aligning with the body’s natural circadian rhythm of growth hormone secretion. We sometimes recommend a five-on two-off approach, where you inject every weekday and take a break on the weekends. The most relevant dosing data come from pediatric studies, where subcutaneous sermorelin is given at 30 micrograms per kilogram body weight once daily. In research studies, dosing is often individualized, with typical starting doses ranging from 100 to 500 micrograms subcutaneously once daily. The dose can be titrated upward based on clinical response, tolerability, and laboratory monitoring, with adjustments made every six weeks as needed.
Rotating injection sites is important to minimize local irritation and prevent lipodystrophy, which is when fat is not uniformly distributed in one area. Compounded sermorelin is usually supplied in multi-dose vials and reconstituted with bacteriostatic water.
Outpatient Monitoring
It would be reasonable to check serum IGF-1 levels 6 weeks after starting therapy and every 6 months after that to ensure that they don’t get too high.
Regular assessment of body weight, body mass index (BMI), waist circumference, and metabolic profile (fasting glucose and lipid panels) is recommended every six months. Bone mineral density should be assessed by dual-energy X-ray absorptiometry (DXA) every 2-3 years, as growth hormone therapies can affect bone metabolism. Thyroid and adrenal function should be evaluated periodically, as GH therapy can unmask or exacerbate underlying endocrine disorders. Sermorelin peptide can also increase the effect of thyroid hormone replacement medications like levothyroxine. These considerations should be discussed with your primary care provider before and after initiating therapy.
Adverse effects of sermorelin are generally mild and reversible with dose reduction. The most common side effects are transient facial flushing and injection site pain. Serious adverse effects are rare, but keep an eye out for signs of leg swelling, joint pain, muscle aches, numbness, or changes to sleep patterns.
Is Sermorelin an option for me?
Ideal patients are motivated to pursue weight loss, able to adhere to a regimen of regular almost-daily subcutaneous injections, and free of contraindications to increased growth hormone activity, such as active cancer or uncontrolled diabetes. We also cannot prescribe it to professional athletes, as it is considered a performance-enhancing drug.
Other benefits of sermorelin include anti-aging properties, improvement of bone density, enhancement of exercise performance and recovery, increased energy, better sleep, nicer skin, improved focus and mental clarity, positive mood, and stronger libido.
In summary, compounded sermorelin peptide therapy is a promising, off-label option for adults seeking weight loss who cannot obtain or tolerate GLP-1 agonists. Its physiologically regulated mechanism of action, favorable safety profile, and customizable dosing make it an attractive alternative to phentermine and orlistat as well. The advantages of compounded medications—improved accessibility, customization, and patient satisfaction—further enhance its appeal. With careful patient selection and individualized dosing, compounded sermorelin can provide meaningful benefits for adults seeking a safe and effective weight loss solution.
Disclaimer
Remember that I’m a doctor, but I may not be your doctor. Please always defer to your own provider’s treatment plan and personalized approach to your health care.
References
- Medications for Obesity: A Review. Gudzune KA, Kushner RF. JAMA. 2024;332(7):571-584. doi:10.1001/jama.2024.10816. Link: https://pubmed.ncbi.nlm.nih.gov/39037780/
- Strategies to Help Patients Navigate High Prescription Drug Costs. Lalani HS, Hwang CS, Kesselheim AS, Rome BN. JAMA. 2024;332(20):1741-1749. doi:10.1001/jama.2024.17275. Link: https://pubmed.ncbi.nlm.nih.gov/39432312/
- Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children With Idiopathic Growth Hormone Deficiency. Prakash A, Goa KL. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 1999;12(2):139-57. doi:10.2165/00063030-199912020-00007. Link: https://pubmed.ncbi.nlm.nih.gov/18031173/
- Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. The Journal of Clinical Endocrinology and Metabolism. 2011;96(6):1587-609. doi:10.1210/jc.2011-0179. Link: https://academic.oup.com/jcem/article/96/6/1587/2833853
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. Fleseriu M, Hashim IA, Karavitaki N, et al. The Journal of Clinical Endocrinology and Metabolism. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118. Link: https://academic.oup.com/jcem/article/101/11/3888/2764912
- American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning From Pediatric to Adult Care. Yuen KCJ, Biller BMK, Radovick S, et al. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2019;25(11):1191-1232. doi:10.4158/GL-2019-0405. Link: https://pubmed.ncbi.nlm.nih.gov/31760824/
Precision Telemed Clickable Links
Compounded Tirzepatide
Compounded Semaglutide
Sermorelin Peptide
NAD+ Injections
Testosterone Replacement Therapy
Hair Loss
Erectile Dysfunction
